ROCKVILLE, Md. - An FDA advisory panel Friday leaned toward favoring Macugen, a proposed treatment for age-related macular degeneration expected to have an impact on the aging Baby Boomer population. (BioWorld Today)

Eyetech Pharmaceuticals Inc. and partner Pfizer Inc. today are scheduled to present data supporting use of the potential blockbuster Macugen as a treatment for neovascular or wet age-related macular degeneration. (BioWorld Today)

Industry has made significant inroads over the years against multiple myeloma - Millennium Pharmaceuticals Inc.'s Velcade, approved in May 2003, comes to mind - but academia also has chalked up important gains against the rare, deadly blood cancer. (BioWorld Today)